Firehawk® Rapamycin Target Eluting Coronary Stent System is the World’s First and Only Target Eluting Stent (TES), which is the new generation product of Shanghai MicroPort Medical (Group) Co., Ltd. following the Firebird and Firebird2 stent to treat coronary artery stenosis or occlusion disease.
- A Stent and Delivery System: L605 CoCr stent pre-mounted to a RX delivery catheter;
- Drug/Polymer Coating: a formulation of rapamycin in a biodegradable polymer coating which filled in grooves that located on outside surface of stent struts.
- Coating exposed area is only 5% of the stent surface
- Polymer fully absorbed.
- World’s lowest drug dosage stent, with only 1/3 dosage versus similar products while achieving the same efficacy
Firehawk is available in different length and diameter of the stent.Firehawk Brochure